Patents by Inventor Sharon A. Baughman

Sharon A. Baughman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment with anti-ErbB2 antibodies
    Patent number: 10280228
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • TREATMENT WITH ANTI-ErbB2 ANTIBODIES
    Publication number: 20190071516
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: November 12, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • TREATMENT WITH ANTI-ErbB2 ANTIBODIES
    Publication number: 20190055317
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Treatment with anti-ErbB2 antibodies
    Patent number: 10160811
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: December 25, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • DOSAGES FOR TREATMENT WITH ANTI-EGFR ANTIBODIES
    Publication number: 20140079692
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • DOSAGES FOR TREATMENT WITH ANTI-EGFR ANTIBODIES
    Publication number: 20130149299
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: March 8, 2012
    Publication date: June 13, 2013
    Inventors: Sharon A. Baughman, Steven Shak
  • Dosages for treatment with anti-ErbB2 antibodies
    Patent number: 7371379
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Dosages for treatment with anti-EGFR antibodies
    Publication number: 20060210561
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: May 31, 2006
    Publication date: September 21, 2006
    Inventors: Sharon Baughman, Steven Shak
  • Dosages for treatment with anti-ErbB2 antibodies
    Publication number: 20040037824
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Application
    Filed: June 20, 2003
    Publication date: February 26, 2004
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Dosages for treatment with anti-ErbB2 antibodies
    Patent number: 6627196
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: September 30, 2003
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Macrocyclic ligands and complexes
    Patent number: 5652361
    Abstract: A group of functionalized polyaminocarboxylate chelants that form complexes with rare earth-type metal ions are disclosed. The complexes, covalently attached to an antibody or antibody fragment, can be used for therapeutic and/or diagnostic purposes.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: July 29, 1997
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, Joseph R. Garlich, Garry E. Kiefer, Kenneth McMillan, Richard Keith Frank, William F. Goeckeler, William A. Fordyce, Roberta C. Cheng, William J. Kruper, Jr., Sharon Baughman, David A. Wilson